title: Xuebijing in the treatment of patients with sepsis.
abstract: BACKGROUND
  There are more than 18 million patients diagnosed with sepsis every year. In China, Xuebijing (XBJ) injection is a traditional medicine that is widely used in the treatment of sepsis. However, the efficacy of XBJ in treatment of randomized controlled trials (RCTs) remains unclear. This meta-analysis was to evaluate the clinical efficacy of XBJ based on randomized case-control studies.
  
  
  METHODS
  PubMed, Cochrane, Embase, Wanfang, CNKI, and WeiPu (VIP) databases were searched to identify all the relative randomized case-control. The latest research was done in June, 2016. Relative risks (RR), weighted mean difference (WMD) along with 95% confidence interval (95%CI) were used to analyze the main outcomes. Statistical analysis was performed using STATA 10.0 (TX, USA). The qualities of the involved articles were accessed by the Jadad scale.
  
  
  RESULTS
  Forty-nine randomized case-control studies met the inclusion and exclusion criteria, with 1861 patients in the control group and 2023 patients in the XBJ group. Compared with the conventional therapy, XBJ injection could significantly reduce the APACHE-IIscore (WMD: -3.70, 95%CI: -4.31-[-3.09]), PCT (WMD: -1.26μg/L, 95%CI: -1.63μg/L-[-0.88μg/L]), WBC (WMD: -1.48×109/L, 95%CI: -2.03×109/L-[-0.94×109/L]), CRP (WMD: -24.38mg/L, 95%CI:-30.49mg/L-[-18.26mg/L]), NEU (WMD: -4.68, 95%CI: -8.32-[-1.04]), T0(WMD: -0.50, 95%CI: -0.92-[-0.07]). The 28-day mortality of the XBJ group was significantly lower than the control group (RR: 0.51; 95%CI: 0.44-0.59).
  
  
  CONCLUSIONS
  XBJ injection has a significant clinical efficacy in the therapy of patients with sepsis. However, there is a need for more randomized, lager-sample size, high-quality, and multicenter studies to confirm the extract efficacy of XBJ injection.
authors.affiliation: Department of Cardiothoracic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China. Electronic address: doctor_zju@126.com.
authors.forename: Heng
authors.initials: H
authors.lastname: Shi
authors.affiliation: Department of Clinical Pharmacology, The First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou 310006, Zhejiang Province, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Hong
authors.affiliation: Department of Cardiothoracic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.
authors.forename: Jianfang
authors.initials: J
authors.lastname: Qian
authors.affiliation: Department of Quality Management, The First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou 310006, Zhejiang Province, China.
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Cai
authors.affiliation: Department of Urology Surgery, The First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou 310006, Zhejiang Province, China.
authors.forename: Shanwen
authors.initials: S
authors.lastname: Chen
mesh_terms: D018806:APACHE; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis
chemical_list: D004365:Drugs, Chinese Herbal; C549376:Xuebijing
keywords: Case-control; Meta-analysis; Randomized; Sepsis; Xuebijing (XBJ)